Results 171 to 180 of about 23,326 (220)
What is the future of acromegaly therapy?
J Clin Endocrinol MetabSchilbach K, Strasburger CJ.
europepmc +1 more source
Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly
Journal of Clinical Endocrinology and Metabolism, 2020 CONTEXT: Reports on the incidence, characteristics, and comorbidity in Asian patients with acromegaly are scarce. OBJECTIVE: To evaluate the incidence of acromegaly and the risk of comorbidities in East Asia, especially South Korea.
Gi Hyeon Seo +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pituitary, 2006
Acromegaly is a slowly progressive disease characterized by 30% increase of mortality rate for cardiovascular disease, respiratory complications and malignancies. The estimated prevalence of the disease is 40 cases/1000000 population with 3-4 new cases/1000000 population per year.
M. Scacchi, F. Cavagnini
openaire +2 more sources
Acromegaly is a slowly progressive disease characterized by 30% increase of mortality rate for cardiovascular disease, respiratory complications and malignancies. The estimated prevalence of the disease is 40 cases/1000000 population with 3-4 new cases/1000000 population per year.
M. Scacchi, F. Cavagnini
openaire +2 more sources
Clinical Endocrinology, 1987
SUMMARYA personal series of 256 cases of acromegaly/gigantism seen over a 20‐year period from 1963 is described. The insidious nature of the condition resulted in delay in diagnosis which was often made by a doctor when seeing the patient for an unrelated problem.
openaire +4 more sources
SUMMARYA personal series of 256 cases of acromegaly/gigantism seen over a 20‐year period from 1963 is described. The insidious nature of the condition resulted in delay in diagnosis which was often made by a doctor when seeing the patient for an unrelated problem.
openaire +4 more sources
New England Journal of Medicine, 1990
Subcellular mechanisms support the notion of an intrinsic pituitary defect in acromegaly, with elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels that affect the cardiovascular and respiratory system, as well as neoplastic cell proliferative activity.
openaire +3 more sources
Subcellular mechanisms support the notion of an intrinsic pituitary defect in acromegaly, with elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels that affect the cardiovascular and respiratory system, as well as neoplastic cell proliferative activity.
openaire +3 more sources
Endocrinology and Metabolism Clinics of North America, 1992
Ectopic acromegaly is a rare syndrome (less than 1% of acromegalic patients) caused by ectopic growth hormone-releasing hormone (GHRH) or growth hormone (GH)-producing tumors. Its recognition is clinically important because acromegaly may be a symptom of an aggressive tumor, and different therapeutic approaches are required.
G. Faglia, M. Arosio, N. Bazzoni
openaire +3 more sources
Ectopic acromegaly is a rare syndrome (less than 1% of acromegalic patients) caused by ectopic growth hormone-releasing hormone (GHRH) or growth hormone (GH)-producing tumors. Its recognition is clinically important because acromegaly may be a symptom of an aggressive tumor, and different therapeutic approaches are required.
G. Faglia, M. Arosio, N. Bazzoni
openaire +3 more sources
Expert Review of Endocrinology & Metabolism, 2007
Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance.
R. Cozzi, R. Attanasio
openaire +2 more sources
Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance.
R. Cozzi, R. Attanasio
openaire +2 more sources